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E-mail: giovanni.camussi@unito.itExtracellular vesicles (EVs) aremembrane vesicles released virtu-
ally by all cell types. Several studies have shown that stem cell-
derived EVs may mimic both in vitro and in vivo the biological
effects of the cells. We recently demonstrated that non-alcoholic
steatohepatitis (NASH) is inhibited by treatment with human
liver stem cells (HLSCs). The aim of the present study was to
evaluate whether EVs released by HLSCs influence the progres-
sion of NASH, induced by a diet deprived of methionine and
choline, in immunocompromised mice. EV treatment was initi-
ated after 2 weeks of diet with a biweekly administration of three
different doses. Bio-distribution evaluated by optical imaging
showed a preferential accumulation in normal and, in particular,
in fibrotic liver. EV treatment significantly improved liver func-
tion and reduced signs of liver fibrosis and inflammation at both
morphological and molecular levels. In particular, we observed
that, out of 29 fibrosis-associated genes upregulated in NASH
liver, 28 were significantly downregulated by EV treatment. In
conclusion, HLSC-derived EVs display anti-fibrotic and anti-
inflammatory effects in a model of chronic liver disease, leading
to an improvement of liver function.
INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) is one of the most com-
mon causes of chronic liver disease. NAFLD progression may lead
to non-alcoholic steatohepatitis (NASH), characterized by liver
inflammation and fibrosis leading to end-stage liver disease, including
cirrhosis and hepatocellular carcinoma.1,2 The establishment of anti-
fibrotic and anti-inflammatory therapies is one of the major clinical
requirement to impinge on liver fibrosis and, especially, NASH.
Human liver stem cells (HLSCs) are an easily obtainable and expand-
able stem cell population derived from human adult liver cells.3,4
HLSCs share with mesenchymal stromal cells (MSCs) the expression
of typical surface markers (CD73, CD29, CD105, CD90, and CD44),
the differentiation capacity (osteoblasts), and the immunomodulatory
properties.3–5 Moreover, HLSCs show a specific hepatic commitment
as they express typical markers of liver cells such as alpha-feto protein,
albumin, and cytokeratins 8 and 18.3,4 HLSCs are negative for the he-Mo
This is an open access article undematopoietic and cytokeratin 19 markers of oval cells and did not ex-
press a-Sma.4 HLSCs are able to differentiate in vitro into functional
hepatocytes and to form islet-like structures.3,6,7 When tested in vivo,
HLSCs are able to improve function and morphology in different
experimental models of acute liver and renal injuries.3,8,9 It has been
recently demonstrated that HLSCs exhibit anti-fibrotic and anti-in-
flammatory effects in a murine model of NASH by regulating specific
genes without the need for differentiation into mature hepatocytes.4
The aim of the present study was to investigate the mechanisms
involved in the anti-fibrotic activity of HLSCs. Previous studies
have shown that extracellular vesicles (EVs) are involved in the para-
crine activity of HLSCs, including anti-fibrotic effects in pre-clinical
models of chronic kidney diseases.10,11 Cell-released EVs are a hetero-
geneous population of membrane vesicles, containing cytosol en-
closed into a lipid bilayer. EVs may transfer their cargo (various types
of RNAs, proteins, and bioactive lipids) from the producing cell to the
recipient cell. EVs derived from different type of stem/progenitor cells
may induce regenerative programs in injured organs/tissues by tran-
scriptional or translational modification in injured target cells.12,13
To investigate whetherHLSC-released EVs (EV-HLSCs) are implicated
in the anti-fibrotic effect of HLSCs, we established a model of NASH
induced by a methionine- and choline-deprived diet (MCDD) in
immunodeficient mice and started a biweekly treatment with EVs after
2 weeks of diet.Mice were sacrificed at week 4; and functional,morpho-
logical, and molecular liver alterations were analyzed.RESULTS
Characterization of EV-HLSCs
We evaluated EV expression markers using a recently described
multiplex bead-based flow cytometry assay platform for EVlecular Therapy Vol. 28 No 2 February 2020 ª 2019 The Authors. 1
r the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Figure 1. Characterization of EV-HLSCs
A multiplex bead-based flow cytometry assay was used to detect EV-HLSC surface signature. 39 multiplexed populations of dye-labeled antibody-coated capture beads
were incubated with 3 different EV-HLSC samples. (A and B) Captured EV-HLSCs were counterstained with pan-tetraspanins APC-labeled (A) or with CD29 APC (B)
detection antibodies. The graph shows a quantification of the median APC fluorescence values for all bead populations after background correction (medium control values
subtracted from measured EV-HLSC values) of three different EV-HLSC preparations. No statistically significant differences were observed among the different EV-HLSC
preparations evaluated. (C) Representative western blot analysis of exosomal markers (CD63, CD9, CD81, and Alix) in the EV-HLSCs. (D) Representative micrograph of
transmission electron microscopy of EV-HLSCs. EVs were negatively stained with NanoVan (scale bar, 100 nm; magnification, 100,000).
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populations, each of them coated with different monoclonal antibodies
against 37 surface antigens andwith two isotypic controls. Sampleswere
detected by counterstainingwith allophycocyanin (APC)-labeled detec-
tion antibodies against specific EV surfacemarkers, such as tetraspanins
(CD9, CD63, and CD81). EVs reacted with beads expressing CD9,
CD63, and CD81. EVs also expressed high fluorescence intensity for
CD29, CD44, CD105, and CD49e. Other markers detected at interme-
diate to low-positive fluorescence intensity comprised mainly CD142,
CD146, SSEA-4, and MCSP (Figure 1). Hematopoietic (CD3, CD4,
CD8, CD19, etc.), endothelial (CD31), and epithelial (CD326) markers
were not detected in EVs (Figure 1A). When using APC-conjugated
anti-CD29 antibody for detection in the same samples, a co-expression
of tetraspanin exosomal markers, MSC markers CD29, CD44, CD105,
CD49e, CD142, CD146, SSEA-4, and the adhesion molecule MCSP
(Figure 1B)was observed.The expression of tetraspaninswas confirmed
by western blot analysis (Figure 1C).
By transmission electron microscopy, EV preparations showed a ho-
mogeneous pattern of nano-sized membrane vesicles (Figure 1D).2 Molecular Therapy Vol. 28 No 2 February 2020EV-HLSCs Improve Liver Function and Morphology of NASH
Mice
To evaluate the potential therapeutic ability of EV-HLSCs on liver
fibrosis and inflammation, we induced NASH by feeding severe
combined immunodeficient (SCID) mice with anMCDD for 4 weeks,
as described previously.4,16–19 Different doses of EVs were adminis-
tered through intravenous (i.v.) injection twice a week, starting at
week 2 of the MCDD (Figure 2A).
Injection of doses 1 and 2 (dose 1: 5  109 EVs per mouse per in-
jection; dose 2: 2.5  109 EVs per mouse per injection) of EVs
induced a significant reduction of alanine aminotransferase
(ALT) in the plasma of NASH mice (Figure 2B). Instead, the
reduction of aspartate aminotransferase (AST) did not reach the
statistical significance (Figure S1A). Serum albumin levels were
increased in NASH mice treated with doses 1 and 2 of EVs,
compared to NASH mice treated with vehicle alone (Figure S1B).
The lower dose tested (dose 3: 2.5  108 EVs per mouse per injec-
tion) did not improve liver function in NASH-treated mice (Fig-
ure 2B; Figure S1). The effect of EVs on liver function, however,
Figure 2. Effect of EV-HLSCs on Liver Function and Morphology
(A) Schematic representation of the experimental design to test EV-HLSCs in NASH
mice, showing the weeks of feeding with MCCD, of EV-HLSC administration, and of
sacrifice. (B) ALT levels expressed as units per liter were measured as a bio-marker
of liver cell injury in serum of control mice (CTRL) and of mice fed with MCDD for
4 weeks treated with vehicle alone (NASH) or with iv injection of different doses of
EVs (dose 1: 5 109 EVs per mouse per injection, n = 9; dose 2: 2.5 109 EVs per
mouse per injection, n = 9; and dose 3: 2.5 108 EVs per mouse per injection, n = 8)
and sacrificed at week 4. (C) Histological quantification of fibrosis in MCDD-fedmice
injected with different doses of EVs or with vehicle alone (NASH) and sacrificed at
week 4 bymultiphase image analyses of 10 fields per section (original magnification,
400). Data shown for ALT and fibrosis represent mean + SD. ANOVA with New-
man-Keuls multicomparison test was performed. *p < 0.05, NASH mice injected
with doses 1 and 2 of EV-HLSCs versus NASH mice treated with vehicle alone. (D)
Representative light microscopy micrographs of liver histology of mice at week 4 of
MCDD, treated with injection i.v. of different doses of EV-HLSCs or with vehicle
alone (NASH) (original magnification, 400). Sirius Red staining showed fibrosis in
the peri-venous area of NASH mice. Red stain represents collagen fibers consid-
ered to be a marker of liver fibrosis.
www.moleculartherapy.org
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probably because the functional contribution of the liver engrafted
HLSCs.Liver fibrosis, as demonstrated by Sirius Red staining, showed an in-
crease in NASH mice in both peri-venous and peri-portal areas (Fig-
ure 2D). Fibrosis was significantly reduced by treatment with doses 1
and 2 but not with dose 3 of EVs (Figure 2C). Treatment with EVs did
not attenuate steatosis (Figure S1C).
Bio-distribution of EVs was performed by i.v. injection of labeled EVs
in healthy and NASH mice. The organ uptake was assessed 3 h after
administration. Accumulation of EVs was most prominent in the
liver and at a low level in lungs, whereas no signal was observed in
spleen and kidney (Figure 3A). Comparing the localization of fluores-
cent EVs in liver of NASH versus control healthy mice, we observed a
significant accumulation of fluorescent EVs in the fibrotic liver (Fig-
ures 3B and 3C). Moreover, in comparing the fluorescent signaling in
lungs of NASH versus control healthy mice, a significant lower accu-
mulation of fluorescent EVs was observed in NASHmice (Figure S2).
This could be due to an enhanced liver uptake of EVs in NASH mice.
EV-HLSC Treatment Downregulates Pro-fibrotic and
Pro-inflammatory Genes in the Liver of NASH Mice
We investigated the possibility that the improvement in liver function
andmorphology after EV treatments may depend on the regulation of
genes that are associated with the induction of fibrosis. To this pur-
pose, liver tissue obtained from NASH mice, treated or not treated
with dose 2 of EVs, was subjected to RNA isolation, and the Mouse
Fibrosis RT2 Profiler PCR Array was performed. The gene expression
profiles of the healthymice andNASHmice treated or not treatedwith
EVs were compared. Figure 4A shows the heatmap of genes expressed
in the experimental groups. Clustering analyses revealed significant
changes in the expression of genes in NASH mice. Twenty-nine
mRNAs out of 84 key genes were upregulated and 9 were downregu-
lated in NASH mice compared to those from the healthy group (Fig-
ure 4B; Table S1). The majority of these genes encoded extracellular
matrix (ECM) remodeling enzymes, transforming growth factor
beta 1 (Tgf-b1) signaling molecules, and inflammatory cytokines
involved in the development of liver fibrosis (Figure 4A). Comparing
to NASHmice, 53 genes were downregulated by EV-HLSC treatment
(Figure 4C; Table S1). Interestingly, 28 out of 29 mRNAs upregulated
in NASH mice were significantly reverted by EV treatment (Fig-
ure 4D). The list of reverted genes included alpha smoothmuscle actin
(a-Sma), Collagen 1a1 (Col1a1), Tgf-b1, and the gene latent-trans-
forming growth factor beta-binding protein 1 (Ltbp1). All these genes
are known to be involved in fibrosis. EV treatment also modulated
genes involved in tissue remodeling and in inflammation, such as
TIMP metallopeptidase inhibitor 1 (Timp-1), matrix metallopepti-
dases (Mmp-1a, -13, -14, and -8), tumor necrosis factor alpha (Tnf),
and interleukin-1 beta (IL-1b) (Figure 4D).
Real-time PCR confirmed that NASH mice had significantly upregu-
lated levels of the pro-fibrotic genes a-Sma, Col1a1 and Tgf-b1 (Fig-
ure 5A) and of the pro-inflammatory genes Tnf, IL-1b, and interferon
gamma (Ifn-g) (Figure 5B). NASH mice treated with EVs had a sig-
nificant reduction in the expression levels of all fibrotic and pro-in-
flammatory genes tested (Figures 5A and 5B). The anti-inflammatoryMolecular Therapy Vol. 28 No 2 February 2020 3
Figure 3. Bio-distribution of EV-HLSCs
(A) Quantification of fluorescence intensity in dissected or-
gans of MCDD-fed mice, measured as average radiance ±
SD at 3 h post-EV-HLSC administration (n = 6). (B) Repre-
sentative images obtained by optical imaging of livers of
NASH and healthy mice, collected 3 h after EV-HLSC or
vehicle administration. (C) Quantification of fluorescence
intensity in livers of NASH and healthy mice injected with
fluorescent EV-HLSCs. **p < 0.01, NASH mice versus
healthy control mice, Student’s t test.
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matory cells accumulated in the liver, as seen by immunofluorescence
staining with the leucocyte marker CD45. Whereas inflammatory in-
filtrates were present in the liver of NASHmice, almost no leukocytes
were detected in mice treated with EVs (Figure 5C). The increase of
interleukin 10 (IL-10) expression level in NASH mice treated with
EVs confirmed the anti-inflammatory effect of EVs (Figure 5D).
EV-HLSC Protein Cargo May Modulate Inflammation
Protein analysis showed the presence of 251 proteins in EVs (Table S2).
Most of the molecules identified are cytokines and growth factors.
Moreover, among the enriched EV proteins, we observed the presence
of transmembrane tyrosine kinase receptors, MMPs, some enzymes
(glutatione reductase, creatine kinase, and aspartate beta-hydroxylase),
and transcription factors. Pathway enrichment analysis showed that
themost enriched pathways were related to cytokine and inflammatory
response, IL-10 anti-inflammatory activity, phosphatidylinositol
3-kinase (PI3K) pathways, and the p53 pathway (Figure 6; Table S3).
DISCUSSION
Results of the present study show that EV-HLSCs exerted beneficial ef-
fects on liver morphology, ameliorating fibrosis and inflammation by4 Molecular Therapy Vol. 28 No 2 February 2020reprogramming liver gene expression. Previous
studies have shown that EVsmay induce epigenetic
changes into recipient cells by transferring
different molecules from the originator cells. It
has been therefore suggested that stem cell-derived
EVs may be exploited to promote tissue regenera-
tion. Previous studies demonstrated that EVs ob-
tained by MSCs of different origin improve acute
liver injuries and increase survival in different
lethal models of liver damages.20,21 Moreover,
MSC-derived EVs were shown to ameliorate he-
patic ischemia reperfusion injury by modulating
the inflammatory response22,23 and by improving
hepatic oxidant injury in toxic24,25 and ischemic26
models. EVs derived from different stem cells
were also studied in different pre-clinical models
of chronic liver injuries. MSC-derived EVs were
able to reduce fibrosis in CCl4- and thioaceta-
mide-induced chronic liver injures by alleviating
hepatic inflammation and collagen depositionand by inhibiting epithelial-to-mesenchymal transition.27–30 More-
over, EVs derived from serum reduced liver fibrosis in mice treated
with CCl4 or thioacetic acid by improving liver function, reducing
hepatocyte apoptosis, and suppressing inflammation.31 These recent
papers indicate that EVs can be exploited for therapy in liver diseases.
EVs show a superior safety profile to cell-based therapy, as they pass
biological barriers and act as effective transporters of different mole-
cules.32 Interestingly, EVs derived from HLSCs preferentially localized
in liver—in particular, in fibrotic areas after systemic administration, as
seen by optical imaging (OI). Different amounts of EV-HLSCs have
been tested inNASHmice.We found that 2.5 109 EVs, injected twice
a week starting at week 2 of an MCDD, are sufficient to obtain amelio-
ration of liver function and morphology and a significant reduction of
the percentage of fibrosis. At the molecular level, we found that 29
genes related to fibrosis and inflammationwere upregulated in the liver
of NASH mice, including transcripts for ECM remodeling enzymes
(mmp-1a, -3, -8, -14, and Timp-1), Tgf-b and Tgf-b signaling mole-
cules, inflammatory cytokines (IL-1b and Tnf-a) and chemokines
(Ccl3 and Ccl2), and chemokine receptor (CXCR4). In the liver of
NASH mice treated with EVs, 28 out of 29 pro-fibrotic genes were
downregulated. Notably, the mRNA expression level of lysyl oxidase
(Lox), which is considered a serum biomarker of liver fibrosis in
Figure 4. Expression of Fibrosis-Related Genes in NASHMice Treated or Not with EV-HLSCs Analyzed through a Fibrosis RT2 Profiler PCR Array (QIAGEN)
(A) Heatmap displaying hierarchical clustering of the entire dataset of expressed genes and indicating co-regulated genes across three different experimental groups: healthy
(CTRL) mice, NASH mice, and EV-HLSC-treated mice. Clustering analysis showed that genes upregulated in NASH mice belong to pro-fibrotic and pro-inflammatory
pathways; EV-HLSC treatment was able to restore their expression to healthy levels (n = 4mice analyzed for each experimental condition). (B and C) The volcano plots identify
significant changes in gene expression between groups: increased number of upregulated genes in NASHmice compared to healthy mice (B) and evident downregulation of
gene expression in EV-HLSC-treatedmice compared to the NASH group (C). The volcano plot displays the statistical significance (p < 0.005) versus fold change on the y and
x axes, respectively. (D) Venn diagram and list of pro-fibrotic and pro-inflammatory genes regulated in NASHmice treated or not treated with HLSC EVs. The expression levels
of genes are presented as fold regulation values (those greater than 1.6 are indicated in red, and those less than 1.6 are indicated in green) for NASH mice compared to
those for controls (NASH vs Ctrl column) and for treated mice compared to those for the NASH group (EV-HLSC vs NASH column). Complete data are provided in Table S1.
www.moleculartherapy.org
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Figure 5. Effect of EV-HLSCs on Liver Fibrosis and Inflammation
(A) Gene expression levels of fibrotic markers (Col1a1, a-Sma, and Tgf-b1) in livers of healthy mice (CTRL) and of NASHmice injected with dose 2 of EV-HLSCs (EV-HLSC) or
with vehicle alone (NASH). *p < 0.05, NASH mice treated with vehicle (NASH) versus normal healthy mice (CTRL); ##p > 0.01, NASH mice treated with vesicles (EV-HLSCs)
versus NASH mice injected with vehicle alone (NASH). (B) Gene expression levels of pro-inflammatory cytokines (Tnf, IL-1b and Ifn-g) in livers of healthy mice (CTRL) and of
NASHmice treated with dose 2 of EV-HLSCs (EV-HLSCs) or with vehicle alone (NASH). For fibrotic and pro-inflammatory genes, data are expressed as relative quantification
using the DDCt method. Normalization was made using GAPDH as a housekeeping gene. An ANOVA with Newman-Keuls multicomparison test was performed. (C)
Representative micrographs of liver cryosections fromNASHmice injected or not injected with dose 2 of EV-HLSCs stained for CD45 to identify the presence of inflammatory
cells. Infiltrates of inflammatory CD45-positive cells (green) were present only in NASH mice that did not receive EV administration. Nuclei were counterstained with DAPI
(blue). Original magnification, 400. (D) Gene expression levels of anti-inflammatory cytokine IL-10 in livers of healthy mice (CTRL) and of NASH mice treated with dose 2 of
EV-HLSCs (EV-HLSCs) or with vehicle alone (NASH). Data are expressed as relative quantification using the DDCt method. Normalization was made using GAPDH as a
housekeeping gene. An ANOVA with Newman-Keuls multicomparison test was performed. **p < 0.01, NASH mice treated with vesicles (EV-HLSCs) versus NASH mice
injected with vehicle alone (NASH).
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the expression levels of Col1a1, Tgf-b1, Ltbp-1, and a-Sma. In partic-
ular, Ltbp-1, which encodes for the protein responsible for activating6 Molecular Therapy Vol. 28 No 2 February 2020Tgf-b1 from its latent form to the active form and which is considered
fundamental for fibrosis progression, was downregulated by EV
treatment.34
Figure 6. Pathway Enrichment Analysis of Proteins Vehicled by EV-HLSCs
(A) Representative bar graph showing the main pathways in which the 251 proteins vehicled by EV-HLSCs, identified by an antibody-based protein array, are involved. Most
of them are related to inflammation and cytokine pathways. Data are ranked according to Z score and are reported in Table S2. (B–E) Bar graph showing the fluorescence
intensity mean (F.U. mean) of the different proteins clustered in the main enriched pathways involved in inflammation: (B) proteins of local acute inflammatory response; (C) IL-
10 anti-inflammatory signaling pathway; (D) cytokines and inflammatory response; and (E) inflammatory response pathway. The complete list of proteins with FU mean
quantitation and pathway enrichment analysis are available in Table S3.
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infiltration of CD45-positive cells was observed in mice maintained
with an MCDD for 4 weeks. NASH mice treated with EV-HLSCs
had a significant reduction of CD45 cell accumulation within the
liver, indicating the anti-inflammatory and immunomodulatory
effects of EVs as detected at the molecular level. Moreover, the expres-
sion of IL-10, an anti-inflammatory and immunomodulatory cyto-
kine,35 was significantly enhanced after EV treatment.
We previously showed in two different models of chronic kidney dis-
eases that the anti-fibrotic effect of EV-HLSCs is linked to the pres-
ence of microRNA (miRNA) patterns targeting the fibrotic genes.10,11
In particular, we found that EV-HLSCs contain miRNA-29a, the let-7
family, miRNA-30a, miRNA-24, and miRNA-21, which are known to
target Collagen I, Snail, and the FAS ligand.11
In the present study, we performed proteomic analyses of EV-HLSCs
showing the presence of several anti-inflammatory proteins that may
contribute to the final anti-fibrotic effect by downregulating inflam-
mation. Therefore, EV-associated proteins may implement the bio-
logical activity of regulatory RNAs present in the EVs.10,11
In conclusion, the results of the present study indicated that EVs
released fromHLSCs exert anti-inflammatory and anti-fibrotic effects
in a model of chronic liver disease by carrying molecules that maymodulate genes involved in fibrosis. Fibrosis is an abnormal mecha-
nism of tissue repair after repeated and sustained injuries that has
common pathways in different organs. Therefore, taking into account
the properties of EV-HLSCs, we can speculate that this may represent
a potential therapeutic approach aimed to modify the abnormal
response of different tissues to injury.
MATERIALS AND METHODS
HLSC Culture
HLSCs were obtained and cultured as previously described.3,4 Briefly,
HLSCs were generated by Anemocyte International (Gerenzano,
Italy) from a 10- to15-mm liver fragment obtained from a liver donor,
according to the standard criteria of Centro Nazionale Trapianti, as
described previously.3,4 The liver fragment was enzymatically di-
gested with good manufacturing practice (GMP)-grade collagenase
(NB 1, 0.6 mg/mL) and neutral protease (NBI, 0.73 mg/mL) for
30 min at 37C. The liver cell suspension was washed (400  g for
10 min) and cultured (2.5  105/mL in a T75 flask with 10 mL per
flask) in the presence of minimal essential medium (a-MEM; Lonza,
Basel, Switzerland) supplemented with 10% fetal calf serum (GIBCO,
Cambrex), 10 ng/mL human recombinant epidermal growth factor
(Miltenyi, Bergisch Gladbach, Germany), 10 ng/mL human recombi-
nant basic fibroblast growth factor (Miltenyi, Bergisch Gladbach,
Germany), 2 nM L-glutamine (Lonza), and 100 U/mL penicillin/
streptomycin (Sigma, St. Louis, MO, USA) and maintained in aMolecular Therapy Vol. 28 No 2 February 2020 7
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were seeded at a density of 2.5  105 cells per flask (T75) in the same
culture medium for expansion.
EV-HLSCs: Purification and Characterization
EVs were obtained from supernatants of sub-confluent HLSCs
cultured in serum-free a-MEM (EuroClone, Pero, Italy) for 18 h.
Viability of cells at the time of supernatant collection was 98%, as
confirmed by trypan blue exclusion. After the removal of cell debris
and apoptotic bodies by centrifugation at 3,000  g for 20 min and
by microfiltration with 0.22-mm filters, EVs were purified by ultracen-
trifugation at 100,000  g for 2 h at 4C (Optima L-90 K; Beckman
Coulter, Fullerton, CA, USA). The pellet of EVs obtained was resus-
pended in RPMI supplemented with 1% DMSO and stored at80C
until use for subsequent studies.
For bio-distribution experiments, EV-HLSCs were labeled during ul-
tracentrifugation with DiD fluorescent dye (Thermo Fisher Scientific,
Waltham, MA, USA) as previously described.36 One micromolar of
Vybrant Cell Tracers DiD was added during the ultracentrifugation
procedure. Then, labeled EVs were washed twice by ultracentrifuga-
tion in PBS (Lonza).
EV-HLSC number was determined using the NanoSight NS300 sys-
tem (NanoSight, Amesbury, UK). EV-HLSC preparations were
diluted (1:200) in sterile saline solution and analyzed using the Nano-
Particle Tracking Analysis (NTA) System with the NTA 3.2 Analyt-
ical Software as described previously.36
EV-HLSCs were characterized by cytofluorimetric analysis. Different
EV-HLSC preparations (n = 3) were subjected to bead-based multi-
plex analysis by flow cytometry (MACSPlex Exosome Kit, human,
Miltenyi Biotec).14,15 Approximately 1  109 EV-HLSCs, quantified
by NTA, were diluted with MACSPlex buffer (MPB) to a final volume
of 120 mL and loaded into a 1.5-mL tube. After this, 15 mL MACSPlex
Exosome Capture Beads (containing 39 different antibody-coated
bead subsets) was added to each tube. For counterstaining of EVs
bound by capture beads with detection antibodies, 5 mL each of
APC-conjugated anti-CD9, anti-CD63, and anti-CD81 detection an-
tibodies was added to each tube and then incubated in an orbital
shaker for 1 h at 450 rpm at room temperature, protected from light.
In this study, we mostly used a mixture of all three antibodies (pan-
tetraspanin) in order to cover most EVs being present in the samples.
In selected experiments, we used 5 mL APC-conjugated anti-CD29
(Miltenyi Biotec) antibody instead of the anti-tetraspanin antibodies.
To wash the beads, 1 mL MPB was added to each tube and washed at
3,000  g for 5 min. This was followed by another washing step with
1mLMPB; incubation in an orbital shaker at 450 rpm, protected from
light for 15 min at room temperature; and then washing at 3,000  g
for 5 min. After washing, 1 mL of the supernatant was carefully aspi-
rated, leaving about 150 mL in the tubes, ready to be acquired.
Flow-cytometric analysis was performed with a CytoFLEX flow
cytometer (Beckman Coulter, Brea, CA, USA). Approximately8 Molecular Therapy Vol. 28 No 2 February 20205,000–8,000 single-bead events have been recorded per sample.
Median fluorescence intensity (MFI) for all 39 capture bead subsets
were background corrected by subtracting respective MFI values
from matched media controls that were treated exactly like EV-con-
taining samples (buffer/medium + capture beads + antibodies). All
bead populations can be identified and gated based on their respective
fluorescence intensity according to the manufacturer’s instructions.
Transmission electron microscopy was performed on EVs placed on
200-mesh nickel formvar carbon-coated grids (Electron Microscopy
Science, Hatfield, PA, USA) and left to adhere for 20 min, as previ-
ously described.37 The grids were then incubated with 2.5% glutaral-
dehyde containing 2% sucrose and, after washings in distilled water,
the EVs were negatively stained with NanoVan (Nanoprobes,
Yaphank, NY, USA) and observed using a Jeol JEM 1010 electron
microscope (Jeol, Tokyo, Japan).
Western Blot Analysis
Protein samples at a concentration of 10–30 mg were separated in 8%
or 4%–15% gradient SDS-PAGE gels under reducing conditions and
electroblotted onto 0.2-mm nitrocellulose membranes (GE Health-
care Life Sciences, Marlborough, MA, USA). The membranes were
blocked in Tris-buffered saline-Tween 20 (TBS-T; 25 mM Tris [pH
8.0], 150 mM NaCl, and 0.05% Tween-20) containing 5% (w/v)
non-fat dried milk for 1 h. After blocking, membranes were probed
overnight with mouse anti-CD63, mouse anti-Alix (both from Santa
Cruz Biotechnology, Santa Cruz, CA, USA), rabbit anti-CD9 (Ab-
cam), and mouse anti-CD81 (Becton Dickinson). After extensive
washings with TBS-T, the blots were incubated with the appropriate
peroxidase-conjugated secondary antibodies for 1 h at room temper-
ature. Following incubation, the membranes were washed extensively
with TBS-T, probed with enhanced SuperSignal West Femto
Maximum Sensitivity Substrate (Thermo Fisher Scientific), and de-
tected with the ChemiDoc system (Bio-Rad, Hercules, CA, USA).
In Vivo Murine Model
Animal studies were conducted in accordance with the NIHGuide for
the Care and Use of Laboratory Animals. All procedures were
approved by the Italian Health Ministry (authorization number:
419/2016-PR).
To evaluate the ability of EV-HLSCs to improve liver fibrosis and
inflammation, we induced NASH by continuously feeding the mice
with an MCDD, as previously reported.4,16–19 Male SCID mice
(Charles River Laboratories, Wilmington, MA, USA), 10 weeks old,
became accustomed to an MCDD (MP Biomedicals, Eschwege, Ger-
many) through a mixture of standard and MCDD chow for 1 week.
Thereafter, the full MCDD was given. Different amounts of EV-
HLSCs were administered via i.v. injection (tail vein) twice a week,
starting at week 2 of the diet (Figure 2), when fibrosis and inflamma-
tion have been established in the liver. Each mouse received a total of
four EV injections. Different doses of EVs were tested: dose 1
(n = 9 mice), 5  109 EVs per mouse per injection; dose 2 (n = 9
mice), 2.5  109 EVs per mouse per injection; and dose 3 (n = 8
Table 1. Real Time PCR Specific Primers and Characteristics of Amplicons
Gene Sense (50/ 30) Antisense (50/ 30)
m-Col1a1 ACCTTGTTTGCCAGGTTCAC ATCTCCCTGGTGCTGATGGAC
m-Tgf-b1 GCAACAATTCCTGGCGTTACC CGAAAGCCCTGTATTCCGTCT
m-a-Sma CATCTCCGAAGTCCAGCACA GACGCACCACTGAACCCTAA
m-IL-1b CAACCAACAAGTGATATTCTCCATG GATCCACACTCTCCAGCTGCA
m-Ifn-g GAGCCAGATTATCTCTTTCATCC GTTGTTGACCTCAAACTTGG
m-Tnf CATCTTCTCAAAATTCGAGTGACAA TGGGAGTAGACAAGGTACAACCC
m-IL-10 GACTTTAAGGGTTACTTGGGTTGC TCCTGAGGGTCTTCAGCTTCTC
m-GADPH TGTCAAGCTCATTTCCTGGTATGA TACTCCTTGGAGGCCATGT
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group was injected with vehicle alone (PBS; n = 23 mice). Control an-
imals (n = 8) were fed with standard diet. All animals were sacrificed
at week 4, and blood and liver were recovered for biochemical, histo-
logical, and molecular analyses.
In Vivo Bio-distribution of EV-HLSCs
Mice fed for 3 weeks with an MCDD and healthy mice were admin-
istered an i.v. injection of 3  1010 fluorescent EV-HLSCs, and their
localization was monitored by OI (n = 6 per group). All the images
have been acquired with the IVIS 200 small animal imaging system
(PerkinElmer, Waltham, MA, USA) using an excitation filter at
640 nm and an emission filter at 700 nm.
Fluorescence analysis was performed by OI on dissected organs 3 h
post-EV injection. Fluorescence emission was normalized to photons
per second per centimeter squared per steradian (p/sec/cm2/sr) as
previously described.36 The fluorescence signal in livers was quanti-
fied in region of interest (ROI) drawn freehand. Data were expressed
as the average radiance ± SD. Images were acquired and analyzed us-
ing Living Image 4.0 software (PerkinElmer).
Histological Analyses
Liver morphology was evaluated through formalin-fixed paraffin-
embedded tissue staining. Paraffin kidney sections (5 mm thick)
were routinely stained for microscopic evaluation with H&E (Merck)
or Sirius Red for collagen detection.
Liver fibrosis was quantified by measuring collagenous fibrotic areas
stained in red (sections stained with Sirius Red) in 10 random fields
per section from images taken at a magnification of 400, using
multiphase image analyses with ImageJ software v1.49.38 The surface
area occupied by steatosis vacuoles was quantified in 10 random fields
per section from images taken at a magnification of 200, using
multiphase image analyses with ImageJ software. Immunofluores-
cence was performed on 5-mm-thick cryostat sections. Sections
were stained with mouse anti-CD45 (Biorbyt, San Francisco, CA,
USA) antibody for 2 h at 4C. Rabbit anti-mouse Alexa Fluor 488
(Molecular Probes) was used as secondary antibody. Hoechst 33258
dye (Sigma) was added for nuclear staining. Confocal microscopyanalysis was performed using a Zeiss LSM 5 Pascal model confocal
microscope (Carl Zeiss International).
Molecular Analyses
Total RNA was extracted from liver tissue of control or NASH mice
treated with or without EV-HLSCs using TRIzol Reagent (Ambion,
Thermo Fisher Scientific, Waltham, MA, USA), according to the
manufacturer’s instructions. The TRIzol solutions were homogenized
in a Bullet Blender instrument (Next Advance, New York, NY, USA)
at a speed of 8 rpm for 3 min using 0.5-mm zirconium oxide beads
and centrifuged at 12,000  g for 15 min at 4C. Supernatant from
homogenized tissue was used to isolate RNA that was quantified spec-
trophotometrically (Nanodrop ND-2000, Thermo Fisher Scientific).
A total of 12 samples, four mice per experimental group, were retro-
transcribed with the RT2 First Strand Kit, and gene expression was
analyzed using the Mouse Fibrosis RT2 Profiler PCR Array
(PAMM-120ZC; QIAGEN, Hilden, Germany) following the manu-
facturer’s protocol. The analysis was performed with the online
QIAGEN software using global normalization. Fold regulation ex-
pressions with respect to the control or NASH group were calculated
for all samples using the DDCt method.
Moreover, to confirm the expression of specific gene expression,
quantitative real-time PCR was performed as described previously.4
Briefly, 5 or 10 ng cDNA, retrotranscribed from RNA using the
High Capacity cDNAReverse Transcription Kit (Applied Biosystems,
Foster City, CA, USA), were used in 20 mL reaction mixture contain-
ing sequence-specific oligonucleotide primers (purchased from
MWG-Biotech, Eurofins Scientific, Brussels, Belgium) and the Power
SYBR Green PCR Master Mix (Applied Biosystems) and were
analyzed with StepOne Plus Real-Time PCR System (Applied Bio-
systems). GAPDH was used as the housekeeping gene to normalize
RNA inputs. Fold change expressions with respect to control were
calculated for all samples using the DDCt method. The primers
used for quantitative real-time PCR are reported in Table 1.
EV-HLSC Protein Content Analysis
EV-HLSC protein content was analyzed with the Human L1000
Array kit (RayBiotech, Peachtree Corners, GA, USA). EV-HLSCsMolecular Therapy Vol. 28 No 2 February 2020 9
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at 4C and then lysed with the lysis buffer provided by the kit
following the manufacturer’s instructions. Protein quantification
was obtained with the Pierce BCA Protein Assay Kit (Thermo Fisher
Scientific). Approximately 25 mg total protein was hybridized onto a
glass slide according to the manufacturer’s protocol. Fluorescence in-
tensity was acquired, and background signal was subtracted for each
point. Cutoff threshold was set at 150 fluorescent units (FUs). Data
are expressed as FUs ± SD.
Pathway Enrichment Analysis
A list of protein vehicles by EV-HLSCs was subjected to bioinformat-
ics analysis by EnrichR39,40 online software. The software provided
different databases, and WikiPathways 2019 was chosen because it
was the most updated one. Pathways were listed and ranked after
Fisher’s exact test was performed for many random gene sets in order
to compute a mean rank and SD from the expected rank for each term
in the gene-set library and finally calculating a Z score to assess the
deviation from the expected rank.
Statistical Analyses
Data analyses were performed using GraphPad Prism 6.0. Results are
expressed as mean ± SD. Statistical analyses were performed by using
an ANOVA with a Newman-Keuls test and Student’s t test for
bio-distribution experiments. A p value of < 0.05 was considered
significant.
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